secwatch.observer — SEC 8-K summary
======================================

Issuer:     GILEAD SCIENCES, INC. (GILD)
CIK:        0000882095
Form:       8-K
Filed at:   2023-08-16T23:59:59+00:00
Accession:  0001104659-23-092665
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gilead reports EVOKE-02 Phase 2 data: SG+Pembro 56% ORR in 1L mNSCLC
--------------------------------------------------------------------

- ORR 69% in PD-L1 TPS≥50% (Cohort A), 44% in <50% (Cohort B); overall ORR 56%.
- Median DOR not reached; 6-month DOR rate 88% in both cohorts.
- Any-grade TEAEs 100%, Grade≥3 70%; 1 treatment-related death (sepsis).
- Data inadvertently posted early by IASLC; Gilead discloses via 8-K.
- Phase 3 EVOKE-03 comparing SG+Pembro vs Pembro monotherapy is ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882095/000110465923092665/0001104659-23-092665-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882095/000110465923092665/tm2323971d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-092665

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer